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Abstract
Malignant Pleural Effusions (MPE) may be useful as a model to study hierarchical progression of cancer and/or intratumoral
heterogeneity. To strengthen the rationale for developing the MPE-model for these purposes, we set out to find evidence
for the presence of cancer stem cells (CSC) in MPE and demonstrate an ability to sustain intratumoral heterogeneity in MPE-
primary cultures. Our studies show that candidate lung CSC-expression signatures (PTEN, OCT4, hTERT, Bmi1, EZH2 and
SUZ12) are evident in cell pellets isolated from MPE, and MPE-cytopathology also labels candidate-CSC (CD44, cMET, MDR-1,
ALDH) subpopulations. Moreover, in primary cultures that use MPE as the source of both tumor cells and the tumor
microenvironment (TME), candidate CSC are maintained over time. This allows us to live-sort candidate CSC-fractions from
the MPE-tumor mix on the basis of surface markers (CD44, c-MET, uPAR, MDR-1) or differences in xenobiotic metabolism
(ALDH). Thus, MPE-primary cultures provide an avenue to extract candidate CSC populations from individual (isogenic) MPE-
tumors. This will allow us to test whether these cells can be discriminated in functional bioassays. Tumor heterogeneity in
MPE-primary cultures is evidenced by variable immunolabeling, differences in colony-morphology, and differences in
proliferation rates of cell subpopulations. Collectively, these data justify the ongoing development of the MPE-model for the
investigation of intratumoral heterogeneity, tumor-TME interactions, and phenotypic validation of candidate lung CSC, in
addition to providing direction for the pre-clinical development of rational therapeutics.
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Introduction
Lung cancer is the leading cause of cancer-mortality in the
world. Current therapy is relatively ineffective, and the 5-yr
survival rate is approximately 15%. Intratumoral heterogeneity
possibly underlies resistance of lung cancers to current therapies;
thus, accounting for intratumoral heterogeneity may be an
important key to developing successful treatment strategies for
lung cancer. Unfortunately, current models of lung cancer are
limited in their scope to study tumor heterogeneity. Malignant
pleural effusions (MPE) offer a unique opportunity to culture a
wide variety of cancer cells from a single individual, in order to
delineate and characterize the range of intratumoral heterogeneity
found in advanced lung cancer.
The rationale for choosing the MPE, a regionally advanced
stage of lung cancer that portends a poor prognosis, as a model to
investigate intratumoral heterogeneity is twofold. First, an
evolutionary model of carcinogenesis predicts that advanced
disease states are more likely to depict heterogeneity [1]. Second,
based on personal observations made over several years of
studying MPE [2,3,4,5], we knew that primary cultures derived
from MPE initially displayed marked culture heterogeneity on
their way to establishing morphologically homogeneous cancer cell
lines. However, we had not previously investigated the biological
or temporal basis of these observations in a prospective manner.
There are no established ways to culture MPE with the goal of
maintaining intratumoral heterogeneity. Thus, we set out to
develop a primary culture model de novo. This model incorporates
the MPE-fluid component and extracted stromal cells in a tumor
microenvironment (TME) that closely simulates the in situ milieu.
Our data indicate that incorporation of these elements seems to
preserve tumor heterogeneity. Since tumor heterogeneity may
arise due to a hierarchical progression of transformed epithelium
[6,7], we hypothesized that included in the mix of tumor cells in
MPE are cells which may function as cancer stem or progenitor
cells. This manuscript provides proof of concept that candidate CSC
can be fractionated from MPE primary cultures. This evidence
justifies the further development of the MPE model for the
examination of intratumoral heterogeneity and the study of
candidate CSC-phenotypes.
Materials and Methods
MPE isolation, processing, and culture
All subjects underwent written informed consent by a process
approved by the institutional review board at the Veterans Affairs-
Greater Los Angeles Healthcare System (VAGLAHS). All subjects
were veterans and active or former smokers, and MPE-specimens
were acquired by large volume thoracenteses. Samples were
processed as described in Figure 1. Briefly, following centrifuga-
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resuspended in a ficoll density gradient. The MPE-supernatant
was sterile filtered and used for the formulation of the primary
culture medium [pcm; DMEM-H (HyClone, UT) +30% v/v
sterilely filtered MPE-fluid component+Penicillin-G/Streptomycin
1000 U/ml and Amphotericin B 0.25 mg/ml (Omega Scientific,
CA)]. The selection of the 30% v/v fraction of the MPE-fluid
component was empirically derived. Because the key soluble and/
or cellular components which contribute to the maintenance of
tumor heterogeneity in MPE-primary cultures is (are) not known,
and since there is effusion-to-effusion variability in the concentra-
tions of soluble factors, the selection of 30%v/v MPE-fluid
component was based on observation of primary cultures by light
microscopy. Briefly, we monitored three different MPEs in
primary cultures containing either 100%, 70%, 50%, 30% and
10% MPE-fluid component. We evaluated culture integrity and
variability by microscopy, and measured the fractions of floating
dead cells (by trypan blue staining) in each condition over several
days. There were no apparent qualitative differences in culture
integrity or variability, and no quantitative differences in floating
dead cells amongst the 70%, 50%, and 30% v/v MPE-fluid
conditions. The 100% and 10% v/v MPE-conditions had an
increase in cell death in two out of three effusions. This
observation, combined with the practical consideration that
MPE-fluid component was the limiting factor for duration of
experimentation with primary cultures, led us to use the 30% v/v
MPE in the remaining cases.
To establish primary cultures, the nucleated cell pellet was
extractedfromtheficoll gradient,washedwith DMEM-H,and after
aliquots were separated for storage, initial molecular analyses and
cytopathology, several primary cultures were seeded. These were
directly observed on a daily basis,and pcm was replaced at every 5–7
days. Kinetic growth analyses of primary cultures were performed
on three distinct MPE specimens. For these determinations,
primary cultures were seeded in parallel in 48 well plates (Corning
Incorporated, NY), at a density of 2610
4 cells/well in 500 mlo f
culture media. To count, floating cells in suspension were collected
first, after which the adherent populations were gently washed with
phosphate buffered saline (PBS), and detached (Trypsin-EDTA,
Sigma MO). The detached cells were then added to the initial cell
suspension, and total live cells (Trypan blue dye exclusion) were
manually counted by hematocytometer at designated time points.
Such studies underlie the reported results that MPE-primary
cultures grew at highly variable and slow growth rates.
Antibodies
The following antibodies were used for immunohistochemistry
(IHC) and/or flow cytometry (FACS): anti-CD 44 (Mouse
monoclonal, Abcam # 16728 for IHC; Mouse Anti-Human
IgG2b CD44-FITC, BD Biosciences # 555478 or PE- labeled
mouse Anti-Human CD44, BD Pharmingen # 555479 for FACS),
anti-uPAR (Mouse monoclonal, Santa Cruz Biotechnology # sc-
13522), anti-ALDH1A1 (Rabbit monoclonal, Abcam # 52492),
anti-CD166 –FITC (Mouse monoclonal; Abcam # 33403);
primary unlabeled anti-cMET (mouse IgG2a, Abcam # 49210),
primary unlabeled anti-MDR-1 (Mouse monoclonal, Chemicon #
Mab4338), and anti-uPAR (Santa Cruz Biotech # 13522).
Secondary antibodies used for the study: Goat F(ab’)2 Anti-Mouse
IgG (H+L)-PE-Cy.5.5 (Caltag laboratories # M35018) and Goat
Anti-Mouse F(ab’)2 IgM (Jackson ImmunoResearch).
Cytopathology and Immunolabeling
Cell clusters were examined using phase contrast microscopy
(Leica - Leitz DMRBE) on covered glass slides, or by light
microscopy following fixation and staining. For the latter, cells
fixed in ethanol (Fischer Scientific, PA) or Z-fix (Anatech, MI)
were sedimented to generate a cell button, which was paraffin
embedded. For IHC, sections (5 mm) were deparaffinized and
rehydrated in xylene and ethanol. Antigen retrieval [10 mM citric
acid (pH 6), 70uC, 30 min, twice with intervening water wash) was
carried out, following which the slides were cooled to room
temperature and sequentially rinsed with deionized water and
PBS. Endogenous peroxidase activity was quenched (PBS +2%
hydrogen peroxide), and the specimens were sequentially blocked
[1% bovine serum albumin/PBS, room temperature 1 hr,
followed by mouse serum (Santa Cruz Biotechnology) for 30
min, room temperature]. Tissue sections were then washed twice
with PBS, incubated with the secondary antibody (HRP-
conjugated Goat anti mouse, Santa cruz Biotechnology, 30 min,
room temperature), rinsed with PBS and exposed to the DAB
substrate kit (Vector Laboratories, Burlingame, CA). Negative
controls typically utilized the secondary antibody alone in the
absence of labeling with the primary. The stained sections were
observed under the microscope (Leica - Leitz DMRBE or
Olympus IX71) and the captured images were analyzed using
the Openlab software. The positively stained cell areas were
estimated using Image Pro Plus software. Cell clusters were
manually defined using phase images and the irregular AOI tool
and the resultant groups were segmented based on an empirically
determined positive staining threshold. Percent of positively
stained cells was estimated based on the fractional area of staining
within the total cluster area.
Reverse transcriptase-PCR (RT-PCR)
RNA was extracted from the primary MPE and culture isolates
using Trizol reagent and Fast Track 2.0 mRNA isolation kit
(Invitrogen Inc., Carlsbad, CA). 500 ng of the mRNA was reverse
transcribed using the RT kit (Invitrogen, Inc., Carlsbad, CA)
following the manufacturer’s recommendations. Two ml aliquot of
the synthesized cDNA was used for PCR for the amplification of
PTEN, Oct4, Bmi1, hTERT, SUZ12 and EZH2 genes. The
primers used were as follows: PTEN Forward - 59 GGAC-
GAACTGGTGTAATGATATG 39, Reverse- 59 TCTACTGTT-
TTTGTGAAGTACAGC 39, Oct4 Forward- 59CAACTCCGAT-
GGGGC CCT 39, and Reverse -59 CTTCAGGAGCTTGG-
CAAATTG 39 Bmi1 Forward - 59 AATCTAAGGAGGAGGTGA
39, Reverse- 59 CAAACAAGAAGAGGTGGA 39, hTERT
Forward -59 GGAATTCTGGAGCTGCTTGGGAACCA 39,
Reverse- 59 CGTCTAGAGCCGGACACTCAGCCTTCA 39,
SUZ12 Forward – 59 GATAAAAACAGGCGCTTACAGCTT
39, and Reverse 59 – AGGTCCCTGAGAAAATGTTTCGA –
39, EZH2 Forward 59 TTGTTGGCGGAAGCGTGTAAAATC
39, Reverse 59 TCCCTAGTCCCGCGCAATGAGC 39. For
PTEN amplification, the conditions were as follows: initial
denaturation at 94uC for 4 minutes, followed by 32 cycles at
94uC for1 minute, 57.5uC for 1 minute, and 72uC for 3 min. A
final extension at 72uC for 10 minutes was utilized. Amplification
conditions for Oct4 were an initial denaturation for 5 min at 95uC,
followed by 32 cycles at 95uC for 30 seconds, 58uC for 30 seconds
and 72uC for 30 seconds with a final extension at 72uC for 5 min.
Amplification conditions for Bmi1: initial denaturation at 94uC for
4 min followed by 32 cycles at 94uC for 1 min, 53uC for 1 min,
72uC for 1 min, and a final extension for 7 min at 72uC. For
hTERT the amplification conditions were: an initial denaturation
at 94uC for 4 min, followed by 32 cycles at 94uC for 50 seconds,
52uC for 50 seconds, 72uC for 1 min, and a final extension at 72uC
for 7 min. For SUZ12 and EZH2 amplification: initial
denaturation at 94uC for 5 min, followed by 30 cycles of 94uC
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final extension at 72uC. PCR products were separated on 8% TBE
(50 mM Tris borate pH 8.0, 1 mM EDTA) gels followed by
Ethidium Bromide staining. Gels were analyzed using the Kodak
1D software.
Flow cytometry and Aldefluor assay
FACS analyses of primary cultured MPE cells was performed by
standard mutichannel FACS analysis using a FACSCalibur
cytometer (Becton Dickinson, San Jose, CA) and FCS Express
analysis software (De Novo Software, Ontario, Canada). Both
non-adherent and adherent cells were collected and pooled. Cells
in primary culture were detached using treatment with Trypsin/
Versine, washed with PBS containing 2% BSA, and directly
labeled with fluorochrome-tagged primary antibodies, or unla-
beled primary antibody with fluorochrome-labeled secondary
antibodies (as indicated below). Both primary and secondary
antibody concentrations were consistently maintained at 1 mg/
1610
6 cells; cells were labeled for 45 minutes at room temperature
and sequentially washed three times in PBS containing 2% FBS,
resuspended in PBS and maintained on ice before FACS analyses.
The Aldefluor (Stemcell Technologies, Durham, NC, USA) assay,
Figure 1. MPE-Fractionation strategy. MPE was extracted from the pleural cavity of lung cancer patients. The collected MPE was sedimented
(2006g) and the cell pellet was separated from the MPE fluid. The cell pellet was resuspended in minimum essential medium containing MPE-fluid and
layered on a Ficoll gradient. The nucleated cell fraction, which was largely devoid of erythrocytes in most cases, was collected from the interpose of
Ficoll gradient and suspension medium, and processed for staining (H&E, IHC), molecular analyses and primary culture. The primary cultures are
maintained in pcm, and are further analyzed for soft agar colony formation, FACS analysis and in vivo tumorigenesis.
doi:10.1371/journal.pone.0005884.g001
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performed according to manufacturer’s guidelines. MPE-cells
from primary culture were suspended in Aldefluor assay buffer
containing the ALDH-substrate, Bodipy-aminoacetaldehyde
(BAAA; 1.5 mM) and incubated for 50 min at room temperature.
To verify specificity, a parallel specimen was incubated under
identical conditions, but in the presence of a 10-fold molar excess
of the ALDH-inhibitor, diethylaminobenzaldehyde (DEAB). This
resultant decrease in the fluorescence intensity of ALDH-positive
cells was used to compensate the flow cytometer analyses.
Results
MPE-characteristics, processing, and primary culture
To develop a model to study lung cancer endophenotypes in
primary culture, we fractionated the cell and fluid compartments
of MPE (Figure 1). The clinical characteristics of the effusions
that were used to generate this dataset were typical of MPE
(Tables 1 and 2, see below). Seven of nine effusions were
malignant on the basis of cytopathological diagnosis (Table 1). In
two MPE, the final cytopathology interpretation from 100 ml
specimen sample was ‘‘highly suspicious but inconclusive’’; these
cases were included because growth of tumor was evident in
primary cultures (including in vivo in one case, data not shown).
Previous studies had long indicated that plating efficiencies and
derivation of primary cultures from clinical lung cancer specimens
is poor, and is dependent both on culture conditions and host-
related factors [8,9,10,11]. However, those studies did not
supplement the primary tumor cultures with components from
the in situ tumor microenvironment (TME), possibly because the
primary or sole goal was to establish immortal tumor cell lines. In
fact, in order to derive ‘‘pure tumor’’ cell lines in defined
conditions, all earlier approaches took measures to minimize the
‘‘contamination’’ of cultures with TME-elements. Consequently, if
distinct tumor cell subpopulations existed in individual tumors that
depended on TME elements for survival, then using any artificial
TME may have conferred a growth advantage to specific tumor
cell subsets in a continuous culture system. Thus, it is possible that
cancer cell models were ‘‘selected for’’ by the culture TME that
was used to derive the tumor cell lines.
We reasoned that the full complement of tumor cell
endophenotypes would be best studied in primary cultures that
incorporated autologous TME. Thus, in an attempt to maintain
intratumoral heterogeneity ex vivo, both the tumor-accompanying
nucleated cell population and the fluid component of MPE were
used to enrich the primary culture-TME. To overcome the
previously recognized inefficiency for establishing primary tumor
cultures, and based on empirical observations described in the
methods, we selected the ‘‘optimal’’ condition as being 30% MPE-
fluid component admixed v/v into base medium containing
antibiotics (primary culture medium, or pcm). In pcm, both
primary culture and serial passages were sustained with higher
diversity in morphology, and cultures appeared to be more robust
(as compared to parallel growth in fetal bovine serum, data not
shown). Moreover, the utilization of a 30% v/v-fraction of MPE-
fluid allowed us to conserve this limiting reagent for longer
durations of experimentation with primary cultures. Using this
methodology, we established primary cultures of MPE-tumors
from all seven attempts.
Preliminary analyses indicated that the supernatant was highly
enriched with inflammatory cytokines, with concentrations of
interleukin (IL) 1, IL 6, C-X-C chemokine ligand 10 (IP10), C-C
chemokine ligand 2 (MCP1), and vascular endothelial growth
factor (VEGF) that were estimated to be .10 ng/ml. These and
other factors, which likely originated from tumor, stromal and/or
circulating cells in MPE (Table 2), contributed to a complex mix
of cytokines, chemokines and growth factors in the MPE-fluid
component. With respect to the cellular MPE-components,
nucleated cell counts ranged from 1.3610
8 to 2.5610
9 cells per
liter of effusion. The predominant circulating cell type in the TME
were lymphocytes (mean6StDev: 60626% out of total 6816560
wbc/ml), with significant (.1%) fractions of PMN, macrophages,
monocytes and mesothelial cells (Table 2) in nearly all effusions.
Thus, in terms of their circulating cell composition and
biochemistry (they were all exudates) [12], the effusions we studied
were typical of MPE.
Evidence of intratumoral heterogeneity in extracted
MPE-tumor specimens
Figure 2A displays representative H&E stained cytopathology
after ficoll density gradation. As shown, the MPE tumor was
variably contained within indistinct clusters of cells of varying
compositions, or as well organized spheroids. Closer examination
suggested that both of these tumor cell conglomerates were
themselves organized into distinct microdomains. We based this
suspicion on the observation that when we labeled specimens for
candidate CSC-markers, we often found staining within discrete foci
in the aggregates (Figure 2B). For example, we stained MPE
pathology specimens for the fractional expression of CD44. CD44,
the cell surface receptor for hyaluronate [13], had been utilized as
a surface label to select CSC. CD44 was previously used alone [14]
and in conjunction with other cell surface markers to sort CSC
from various epithelial malignancies, in both human and murine
model systems [15,16,17,18,19,20,21]. All MPE specimens
displayed a CD44+ fraction, which ranged from an estimated
8% to 47% of nucleated cells by immunohistochemistry (IHC)
(Figure 2B, Figures S1a and S1c). In addition to CD44, cell
fractions also displayed other candidate CSC-markers, cMET
[22,23] and MDR-1 [24,25] (Figure 2B). Previously, other
researchers had also exploited differences in xenobiotic metabo-
lism of cells to segregate CSC from the tumor mix. One such
technique utilized the Aldefluor
TM assay (StemCell Technologies),
which segregated candidate CSC on the basis of ALDH1A1 activity
[26,27,28]. Like CD44, we found that cells that labeled for
ALDH1 were seen in aggregated pockets within MPE-tumors
(Figure 2B, Figure S1b). Marked variability of staining was
evident even within an individual specimen. Thus, one could find
discrete pockets of weak, medium and strong ALDH1 staining
Table 1. Cytopathology of MPE and their in vitro growth.
Subject Cytopathology In vitro growth
106 NSCLC ND
206 AdenoCa ND
107 NSCLC yes
207 Suspicious, NSCLC yes
307 Large Cell Ca yes
407 AdenoCa yes
507 NSCLC yes
607 Suspicious, SCCa yes (primary passage path c/w SCCa)
707 Poorly differentiated SCCa. yes
AdenoCa denotes lung adenocarcinoma, NSCLC denotes Non Small Cell Lung
Cancer (not specified), SCCa denotes lung squamous cell cancer, ND denotes
not determined).
doi:10.1371/journal.pone.0005884.t001
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specimens had diverse immuno- and metabolic phenotypes.
Moreover, if the candidate CD44 and ALDH-labels were valid
surrogate markers for CSC, then CSC seemed to reside in discrete
protected microdomains (niches) in the MPE-tumor clusters.
Finally, although the temporal expression and functional correla-
tion of these CSC-labels has yet to be determined, the data
suggested that cells expressing candidate CSC markers could be
potentially separated from the MPE-tumor mix.
MPE-tumors express CSC-markers implicated in
progenitor cell expansion or pluripotency programs
In general, tumors arise because of an abnormal arrest during
tissue-differentiation [29,30]. One of the first manifestations of the
differentiation-arrest is that there is an expansion of the progenitor
cell pool. Thus, molecular signatures of progenitor cells may serve
as candidate CSC-biomarkers. In this regard, animal studies had
implicated PTEN for the appropriate maintenance and differen-
tiation of the peripheral lung progenitor cell population [31].
PTEN promoter silencing is evidenced in human lung cancer [32],
implicating this pathway in its development and/or progression.
Telomerase (hTERT) activation contributes to lung cancer
pathogenesis [33], and hTERT is commonly activated in lung
cancer. Along with p16 (INK4A), hTERT seems to be required for
cell immortality that characterizes both stem cells and tumor cells
[34], and its expression may indicate a dynamic change in the
fraction of the immortalized phenotype [35,36]. Shared markers
between candidate CSC and stem cells also include pathways that
mediate cell self-renewal and pluripotency. Oct4 is an embryonal
marker that is associated with pluripotency, and is commonly used
to label the CSC-phenotype [21,37]. Similarly, the regulation of
the pluripotent state is epigenetically controlled by structural
changes in chromatin [38,39,40]. Transcriptional control during
the pluripotent state is applied by the polycomb group (PcG) of
proteins that work to modify chromatin structure. SUZ12, EZH2,
and Bmi1 are components of PcG complexes, and because their
expression in development is characteristic of tissue stem cells, they
have also been used to label the candidate CSC-phenotype [6,7,41].
To test if these molecular signals of candidate CSC could be
detected in MPE-tumors, RNA was extracted from the nucleated
cell fractions and RT-PCR for these markers was performed. We
found that these candidate CSC-biomarkers were expressed in
different MPE-tumors (Figure 3). These data suggested that the
lung CSC-phenotype was maintained in MPE despite the
inflammatory milieu of the MPE-TME, contrary to some
conventional postulates regarding the CSC niche environment.
Perhaps, this was because the CSC were protected (as described)
from the soluble TME in the tumor conglomerates that are
evidenced in MPE. More importantly, these results also set the
stage for dynamically tracking these molecular signals as
experimental changes into the culture conditions are introduced
in efforts to enrich for the CSC-phenotype.
Evidence of intratumoral heterogeneity in MPE-primary
cultures
MPE-primary cultures were established in pcm. In these
conditions, the primary cultures displayed diverse morphologies
(Figure 4A), and variably slow growth rates. The primary cultures
typically took several weeks to ‘‘mature’’ (as defined by growth in
the culture vessel approaching 70–80% confluence). Over this
interval, the clusters and spheroidal structures that were observed
in the initial MPE-cytopathology were not well conserved.
Nevertheless, the primary cultures displayed a phenotypic
heterogeneity that had not previously been examined. During
their evolution, primary cultures were always comprised of
colonies with varying morphologies (floating aggregates that
exclude trypan blue, giant cell colonies, fibroblastoid and
cobblestoned clusters), despite being in the same flask with an
apparently identical TME (Figure 4A). These colonies seemed to
expand at varying rates, suggesting that they had different
proliferative indices, despite being in a ‘‘common’’ environment.
We reasoned that if CSC, like tissue progenitor cells, had a
reduced turnover, then differences in proliferation would allow us
to segregate fractions enriched for CSC. To test whether such a
strategy was feasible with MPE- primary cultures, we developed a
live cell sorting strategy that used carboxyfluoroscein succinimidyl
ester (CFSE) in a test-labeling scheme to fractionate cells based on
different replication indices. CFSE is a membrane permeable
reagent that is cleaved by intracellular esterases to yield a
fluorescent amine-reactive metabolite which remains in the
cytoplasm for weeks. Every time cells undergo division, the
amount of CFSE present in each daughter cell is halved. Cells that
are not replicating retain the label. Thus, if CSC are slowly
replicating, then the label retaining population should be enriched
for CSC. Although the cellular lineages that comprise the label
retaining subset need to be better defined, these pilot, proof-of-
concept studies suggested that MPE-tumor fractionation based on
differences in proliferation indices was feasible (see the label-
Table 2. Non Tumor Cellularity of the MPE.
MPE Cell Counts and Differentials Mean6Standard Deviation (n=9) MPE in which wbc-diff is $1% total
RBC 1580616172443 rbc/mlN / A
WBC 6816560 wbc/ml9 / 9
Lymphocytes 60626% 9/9
PMN 23627% 8/9
Monocytes 363% 9/9
Macrophages 668% 8/9
Mesothelial Cells 464% 8/9
Other (eosinophils, plasma cells) 6613% 4/9
Counts and differential were obtained by manual cytometer reading of Giemsa-Wright stained cytology slides in the VAGLAHS hematopathology laboratory. The data is
cumulatively presented. The numbers in column two indicate the numbers and percentages of various cell types, and column three indicates the fraction of MPE in
which the various cell types were identified. These data affirm that the cell counts of the effusions collected were typical of MPE.
doi:10.1371/journal.pone.0005884.t002
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PLoS ONE | www.plosone.org 5 June 2009 | Volume 4 | Issue 6 | e5884Figure 2. (A) Representative cell clusters and spheroids in MPE-cytopathology. Representative H& E of tumor specimens derived from MPE
showing clusters and organized spheroids of varying morphology, and cell/stromal compositions (206or 1006). (B) IHC for candidate CSC
marker expression. Tumor specimens derived from MPE were immunolabelled for candidate CSC markers, including CD44 (406and 4006), cMET
(1006and 4006), MDR-1 (1006and 4006), and ALDH-1 (406and 2006).
doi:10.1371/journal.pone.0005884.g002
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Figure 4B). In summary, differences in morphology, prolifera-
tion, surface marker and metabolic properties possibly reflect
discrete endophenotypes of cancer cells in MPE. Although the
functional correlates associated with each of these features have yet
to be further explored, our results indicate that in MPE-primary
cultures, the investigation of intratumoral heterogeneity is feasible.
Rationally fractionating MPE-primary cultures to sort the
putative CSC-subpopulation
With molecular signatures suggesting that CSC are present in
MPE, we next tested if we could capture the candidate CSC from
MPE-tumors. On maturation, MPE-primary cultures were sorted
on the basis of candidate CSC-markers. Interestingly, in each case
tested so far, the surface immunophenotype of cells in primary
culture generally indicated an apparent expansion in the CD44+
fraction (Figure 5). Whereas cells were nearly uniformly positive
for CD44 expression, fractions were more variably positive for
cMET, CD166 [42], and uPAR [43] expression (Figure 5).
Additionally, using a fluorescent assay that was reported to sort
putative CSC from lung cancer, breast cancer, and multiple
myeloma [26,27,28] on the basis of differential ALDH activity, a
small fraction of the MPE-derived primary tumors displayed the
ALDH
hi/CD44
+ phenotype (Figure 6). Collectively, these data
indicated that candidate CSC-fractions could be segregated from
primary cultures of MPE-tumor. In future studies, these fractions
can now be compared to isogenic tumor cells for validation of the
candidate ‘‘CSC-phenotypes’’ by bioassay.
Discussion
Lung cancer is the leading global cause of cancer death in both
men and women [44], but its molecular and cellular pathogenesis
is not well understood [45]. Lung cancer diagnoses within the four
major histological types are based on the preponderance of a
specific histopathology by light microscopy. However, intratu-
moral heterogeneity has long been recognized to be a common
occurrence in lung cancer [46,47,48,49,50]. This heterogeneity is
evidenced throughout the course of the disease; cigarette smoke-
exposed lung mucosa that appears morphologically normal
displays diverse gene-expression profiles during pre-malignancy,
and many/most lung cancers display mixed morphologies. Our
overall hypothesis is that the observed differences in the molecular
and morphological features of different tumor cells in individual
lung cancers may have functional correlates.
Unfortunately, current models of lung cancer are limited in
their scope to study tumor heterogeneity. Transgenic animal
models are only provisional models for human disease for several
reasons. For example, there are significant differences in the
comparative anatomy and physiology between the mouse and
human lung and there is a lack of certainty regarding the key
gatekeeper mutations that result in the development of lung cancer
in humans. Thus, the applicability of animal models to human
disease remains imprecise. Similarly, current clinical research
paradigms often survey genomic and gene expression profiles to
catalog subtypes of lung cancer for diagnostic and prognostic
purposes. However, data acquisition for genetic array analyses also
overlooks tumor heterogeneity. Thus, even when methods for
molecular profiling aim to collect data from ‘‘homogeneous’’
samples, inconsistencies in both the genomic and expression
signatures remain evident. These inconsistencies likely reflect both
inter- and intra-tumoral heterogeneity, and a new, complementary
phenotype-based approach to stratify and prognosticate lung
cancer should be considered. Here, we have provided proof of
concept that MPE-primary cultures may be used to investigate
intratumoral heterogeneity and to isolate candidate lung CSC. In
this respect, our results not only advance the notion that there is
diversity, but that this diversity can now be studied in culture,
using methods we have described in this report.
The mechanisms underlying the development of tumor
heterogeneity are unclear. Perhaps, this heterogeneity is attribut-
able to an evolutionary process [1], and/or it may be the
culmination of hierarchical progression of disease [6,7]. Either
way, our MPE-model offers a unique opportunity to culture a wide
variety of cancer cells from a single individual, and to
experimentally determine the molecular basis for an observed
Figure 3. MPE primary cultures express candidate CSC-molecular markers. Expression profiles of PTEN, Oct4, hTERT, BMI1, SUZ12, and EZH2 were
studied by reverse transcriptase-PCR. RNA extracted from the nucleated cell pellet of MPE was reverse transcribed and the cDNA was used in the PCR-
amplification of the respective genes. PCR products were separated on 10% TBE gels, followed by ethidium bromide staining, and analyzed using the
Kodak 1D software. PTEN, hTERT, SUZ12, EZH2 were uniformly expressed in all MPE, while BMI1 and Oct4 expression was not detected in individual
samples. Beta tubulin was used as a loading control.
doi:10.1371/journal.pone.0005884.g003
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(CSC)-hypothesis argue that rare cancer cells bearing stem cell
traits can be isolated from advanced tumors, and that these cells
can recapitulate the full heterogeneity evidenced in the parental
tumor in implanted xenografts [14,15,18,27,28,42,51,52,
53,54,55,56]. CSC may also be endowed with programs that
form the basis for cytotoxic drug resistance [57] and tumor
invasion. However, it is also recognized that in advanced
malignancies, ‘‘undifferentiated’’ cancer cells emerge, which often
display epithelial to mesenchymal transition (EMT) and are
associated with the acquisition of invasive traits [19,41].
Importantly, the undifferentiated cells have overlapping features
with the stem cell phenotype. For lung cancer, it is not known
whether the undifferentiated cells bearing stem cell features in
advanced malignancy are in fact bona fide CSC. However, to
answer this important question, the MPE-model is an appropriate,
clinically relevant prototype to determine if cells that are
segregated on the basis of candidate CSC markers are predictive
of a distinct tumorigenic or invasive phenotype.
To ascertain the role of CSC in lung cancer pathogenesis,
several groups have embarked on independent efforts to isolate
and characterize candidate lung CSC [24,42,58,59,60]. Each
investigator has employed different tactics and models to
characterize lung CSC. Our efforts are unique in that we utilize
clinical MPE specimens, and establish primary culture in an
autologous culture TME. It remains to be seen whether such
differences in techniques or sources of tumor will translate into
differences in the cancer endophenotypes that are selected, or
differences in the biological profiles of the candidate CSC which
emerge from these efforts. Our approach clearly poses several
important challenges. The kinetics of primary cultures are very
variable, and importantly, colony-growth within an individual
culture is heterogeneous. Observations of primary cultures enable
us to envision how the process of establishing model immortalized
cell lines may select the most resilient tumor cell subpopulations in
a given culture environment over time, while leaving a fraction or
major proportion of cells extinct. If that is the process by which cell
lines are developed, then the contributions of the extinct
subpopulations would be largely unaccounted for in cell line
models. Based on our early observations, we postulate that our
model enables the prolonged maintenance of some tumor cell
subpopulations that would have died out in other conditions.
Although the key soluble and/or cellular components which
contribute to the tumor heterogeneity and/or maintenance of the
candidate CSC in MPE-primary cultures have yet to be defined, it is
important to note that cells bearing surrogate labels for cancer
stem cells are included in the MPE-tumor mix.
However, we also note that our primary cultures evolve in terms
of their structure and cellular compositions as they expand in vitro.
The markers and labels that are used to identify and extract CSC
Figure 4. (A) Morphological heterogeneity in primary culture. Three different MPE (Sample A, Sample B and Sample C) cultured in pcm were
evaluated for colony morphology. Each column (A, B, and C) represents a distinct specimen. Representative photomicrographs of colony
heterogeneity by phase-contrast microscopy on days 3, 15 and 20 of primary culture (rows 1, 2 and 3, respectively) are presented. The
photomicrographs in Rows 1, 2 and 3 are at magnifications of 406, 1006and 4006, respectively. (B) MPE-subpopulations in primary culture
can be fractionated on the basis of differences in proliferation: Representative flow histograms of Day 1 versus Day 9 of a CFSE-labeled
primary culture. With expansion, subpopulations that are proliferative lose the CFSE label, and those which are quiescent retain the label. In this
example, on day 1, 96.14% of the counts lie within the region gated by M1;o nday 9, 8.36% of the counts lie within the region gated by M1.
doi:10.1371/journal.pone.0005884.g004
Cancer Stem Cells in MPE
PLoS ONE | www.plosone.org 8 June 2009 | Volume 4 | Issue 6 | e5884Figure 5. Fractional expression of candidate CSC-markers by FACS in MPE-primary cultures: Standard multi-channel FACS analyses of
primary cultured MPE cells was performed using pooled MPE culture cells. Three different MPE (Sample A, Sample B and Sample C)-primary cultures
in pcm were collected and labeled for candidate CSC-marker expression (CD44, cMET, CD166, MDR-1 and uPAR). Numbers at the upper right corners
of each FACS-histogram represent the % of cells that are positive, as defined by cells displaying fluorescence exceeding the 95th percentile of cells
stained with isotype matched control antibody.
doi:10.1371/journal.pone.0005884.g005
Cancer Stem Cells in MPE
PLoS ONE | www.plosone.org 9 June 2009 | Volume 4 | Issue 6 | e5884also display dynamic changes. Based on our observations, if these
candidate labels are valid surrogates for the CSC-phenotype, then
we cannot be confident that this is a ‘‘rare’’ population. One
possibility for the observed changes is that they represent the
transition between the in situ to the in vitro state. As described, the
well organized 3-dimensional tumor spheroids/clusters that are
extracted from the patient are not well preserved in primary
culture. It is possible that as the relatively organized structures
disintegrate in vitro, the cancer cells within are exposed to soluble
factors that are typically excluded from the extracellular matrix in
the organized structures in situ. Perhaps, upon being exposed to
novel factors and cytokines in the MPE-fluid microenvironment,
the tumor cells are induced to undergo epithelial to mesenchymal
transition (or a transition to the candidate CSC-phenotype). Either
way, whether the candidate CSC markers can be specifically
correlated with a distinctive phenotype needs to be experimentally
determined, and our MPE-culture model will allow us to make
these determinations.
At this juncture, our studies are unable to provide definitive
proof that a discrete subpopulation of tumor cells within the MPE
is capable of more efficient tumorigenesis than isogenic counter-
parts in an in vivo model. Although not described earlier in this
report, the prospective experimental design and model (subcuta-
neous implantation of tumor in scid mice) we utilized for a
phenotypic readout did not yield tumors with high efficiency from
primary MPE isolates, and did not enable us to establish a reliable
baseline for the cell numbers needed for in vivo tumorigenesis.
Although one can invoke many reasons for why the phenotypic
outcome measure we chose failed, the exercise was empirically
informative by suggesting that a new transplantation model will
likely need to be developed. Thus, in future studies that are
undertaken to compare engraftment efficiencies of candidate CSC
versus isogenic control tumor cells by limiting dilution analyses, we
have proposed to develop a new animal transplantation model.
Given that a recent report suggested effective transplantation of
TME components along with tumor cells in a transplantable
animal model of lung cancer [61], we envision that this model may
prove useful for our purpose.
Importantly, in an effort to develop alternative phenotypic
outcome measures to select the candidate CSC-phenotype, we were
able to establish cultures in vitro with high efficiency (7/7 attempts),
using the novel strategy that utilized an autologous tumor
Figure 6. Aldefluor positive expression in MPE-primary cultures. Depicted are FACS-dot histograms of two distinct MPE-primary cultures.
The intensity of Aldeflour expression (representing ALDH-activity) is on the abscissa; intensity of CD44 expression is on the ordinate. The dot plot
figures on the left panel show control (ALDH-negative) cells in presence of ALDH inhibitor DEAB (+DEAB, negative control); ALDH-positive cells are
shown in the right panel in Gate 3, in the absence of DEAB. Aldefluor+cells are depicted in gate 3; note that these cells also stain intensely for CD44.
doi:10.1371/journal.pone.0005884.g006
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able to provide a proof-of-concept that 1) candidate lung CSC are
present in this milieu, 2) candidate lung CSC can be maintained
over time in this primary culture environment, and 3) that we can
live sort candidate lung CSC from these primary cultures to evaluate
their phenotype in various bioassays. These new developments set
the stage for experimentation along pathways that are distinct
from in vivo tumorigenesis by limiting dilution analyses. For
example, we can now propose to test whether MPE-tumors that
are segregated on the basis of candidate CSC-markers will display
differences in in vitro surrogate measures of the CSC-phenotype
(soft-agar colony formation, drug resistance, and/or matrigel
invasion) from isogenic tumor cells that don’t express candidate
CSC markers. In summary, our results argue for the ongoing
development of the MPE-primary culture model, and set the stage
for correlating observed phenotypic differences with distinctive
molecular signatures. Our hope is that by characterizing the
molecular basis for specific tumor endophenotypes in MPE, we
will be able to better design rational therapeutic combinations that
are more predictive of clinical efficacy.
Supporting Information
Figure S1 Figure S1a: Representative images of CD44 staining
with negative controls. Figure S1b: Representative images of
ALDH staining with negative control. Figure S1c: Additional
representative images depicting CD44 staining within microdo-
mains of MPE-tumor clusters.
Found at: doi:10.1371/journal.pone.0005884.s001 (7.73 MB TIF)
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